patent expiry

Losing patent protection on a product, letting generics and biosimilars take its sales.

Exposure · 10 companies

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ABBV AbbVie

    Exposed“As products lose exclusivity, generic and biosimilar competition may accelerate erosion.”

    Latest 10-QQ3 FY2026Positive ·

    Skyrizi and Rinvoq more than offset Humira erosion; lower acquired R&D and impairment charges amplify the earnings rebound.

    • Revenue$17.4BYoY +10.3%
    • Net income$4.2Bvs $186.0M year ago
  • AMGN Amgen

    Exposed“For example, our patents for RANKL antibodies, including sequences, for Prolia and XGEVA expired in February 2025 in the United States and in November 2025 in select countries in Europe, and we expect accelerated sales erosion driven by increased competition, as multiple biosimilars have launched in the United States and ROW.”

    Latest 10-QQ3 FY2026 ·

    Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.

    • Revenue$10.4BYoY +8.5%
    • Net income$3.9BYoY +20.1%
  • BMY Bristol-Myers Squibb

    Exposed“Upon the expiration or loss of market exclusivity on a product, we can lose the major portion of that product's revenue in a very short period of time.”

    Latest 10-QQ3 FY2026MixedImpairment / charge ·

    Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.

    • Revenue$13.1BYoY +6.9%
    • Net income$2.2BYoY −1.8%
  • GILD Gilead Sciences

    Exposed“Patents, licenses, trade secrets, and successful defense against generic challenges are central to Gilead’s business.”

    Latest 10-QQ3 FY2026Impairment / charge ·

    Acquisition charges and the EVOKE-03 write-off drove a YTD loss despite stronger Biktarvy and Yeztugo sales.

    • Revenue$8.3BYoY +6.8%
    • Net income$2.4BYoY −20.4%
  • JNJ Johnson & Johnson

    Exposed“Loss of exclusivity can lead to substantial sales declines for Innovative Medicine products as generics and biosimilars enter.”

    Latest 10-QQ3 FY2026MixedRestructuringImpairment / chargeLegal / investigation ·

    TREMFYA and oncology growth offset STELARA’s biosimilar erosion, but a proposed talc-settlement charge nearly wiped out earnings.

    • Revenue$25.4BYoY +5.9%
    • Net income$210.0MYoY −95.9%
  • LLY Eli Lilly and Company

    Exposed“Loss of effective patent protection for pharmaceuticals can result in the loss of effective market exclusivity for the product, often leading to a severe and rapid decline in revenues for the product.”

    Latest 10-QQ3 FY2026PositiveImpairment / charge ·

    Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.

    • Revenue$24.4BYoY +38.6%
    • Net income$6.5BYoY +15.5%
  • LYCA Lycia Therapeutics, Inc.

    Exposed“Applications may not issue, patents may be narrow, challenged, invalidated, designed around or expire after development consumes much of their term.”

    Latest 424B4final IPO prospectusMixedPre-revenue ·

    Develops protein degraders for food allergy and Graves’ disease; raises $318M gross to advance clinical trials.

  • MRK Merck & Co.

    Exposed“Generic and biosimilar competition, stronger branded alternatives, patent challenges, and varying intellectual-property protections across countries could reduce sales, sometimes rapidly after exclusivity ends.”

    Latest 8-KLeadership change ·

    Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.

  • PFE Pfizer

    Exposed“The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments and the expiration of co-promotion and licensing rights can have a material adverse effect on our revenues.”

    Latest 8-KCEO/CFO change ·

    Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.

  • REGN Regeneron Pharmaceuticals

    Exposed“EYLEA’s U.S. regulatory exclusivity expired in May 2024, and biosimilars have launched in the U.S. and certain international markets.”

    Latest 10-QQ3 FY2026Positive ·

    Dupixent growth and richer Sanofi profit sharing more than offset EYLEA erosion, deepening reliance on the partnership.

    • Revenue$5.1BYoY +36.3%
    • Net income$1.9BYoY +33.5%

Feedback